Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195)
Business Segments1) Biosimilars (58% in FY25 vs 50% in FY23):[1][2]Biocon Biologics develops and markets a range of 20 biosimilars including insulins, monoclonal antibodies, and conjugated recombinant proteins across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases.[3]It isone of the top 5 global players in biosimilars and among the top 3 in insulins. It ranks in thetop 15 companies worldwide for biomanufacturing capacityand has a presence in 120+ countries, including the U.S., Europe, and emerging markets. Its product portfolio includes 10 approved biosimilars and 10 under development.[4]The segment revenue grew by 2% YoY in FY25, driven by market share gains in the U.S. and key tender wins in the Emerging Markets.[5]
| S.No. | Name | Current Price (Rs.) | Price to Earning | Market Capitalization (Rs.Cr.) | Dividend yield (%) | Net Profit latest quarter (Rs.Cr.) | YOY Quarterly profit growth (%) | Sales latest quarter (Rs.Cr.) | YOY Quarterly sales growth (%) | Return on capital employed (%) | Sales (Rs.Cr.) | OPM (%) | Profit after tax (Rs.Cr.) | Profit after tax latest quarter (Rs.Cr.) | Price to book value | Return on assets (%) | Debt to equity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Sun Pharma.Inds. | 1782.60 | 37.05 | 427717.60 | 0.90 | 3124.95 | 2.56 | 14478.31 | 8.93 | 20.21 | 54964.01 | 30.12 | 11543.96 | 3117.95 | 5.50 | 12.97 | 0.07 |
| 2. | Divi's Lab. | 6642.50 | 70.94 | 176292.38 | 0.45 | 689.00 | 35.10 | 2715.00 | 16.12 | 20.44 | 10029.00 | 32.37 | 2485.00 | 689.00 | 11.44 | 13.53 | 0.01 |
| 3. | Torrent Pharma. | 4092.20 | 63.93 | 138496.88 | 0.78 | 591.00 | 32.49 | 3302.00 | 14.30 | 27.05 | 12248.00 | 32.60 | 2166.53 | 600.17 | 16.39 | 13.26 | 0.33 |
| 4. | Cipla | 1467.90 | 21.80 | 118607.61 | 0.89 | 1353.37 | 3.73 | 7589.44 | 7.64 | 22.72 | 28349.57 | 25.40 | 5441.14 | 1351.17 | 3.60 | 14.72 | 0.01 |
| 5. | Dr Reddy's Labs | 1242.80 | 17.97 | 103748.51 | 0.64 | 1336.80 | 7.28 | 8828.30 | 9.83 | 22.69 | 34310.00 | 24.64 | 5772.20 | 1347.10 | 2.88 | 12.95 | 0.16 |
| 6. | Lupin | 2214.30 | 23.36 | 101043.20 | 0.54 | 1484.83 | 73.34 | 7047.51 | 24.23 | 21.30 | 24750.69 | 27.25 | 4324.63 | 1477.92 | 5.15 | 12.41 | 0.32 |
| 7. | Mankind Pharma | 2311.80 | 54.55 | 95387.58 | 0.04 | 520.18 | -22.00 | 3697.16 | 20.77 | 15.98 | 13545.67 | 24.12 | 1748.55 | 511.51 | 6.24 | 8.89 | 0.55 |
| 8. | Biocon | 387.05 | 645.39 | 51760.61 | 0.13 | 70.90 | 2115.62 | 583.30 | 11.02 | 2.09 | 2327.00 | 7.17 | 80.20 | 70.90 | 3.24 | 0.30 | 0.16 |
| – | Median: 150 Co. | 409.67 | 30.81 | 1757.37 | 0.11 | 13.03 | 12.32 | 157.2 | 10.8 | 14.98 | 582.87 | 15.93 | 44.55 | 13.73 | 3.24 | 8.6 | 0.22 |
Standalone figures in ₹ crores
| Dec 2022 | Dec 2023 | Dec 2024 | Jun 2023 | Jun 2024 | Jun 2025 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 555 | 563 | 563 | 513 | 511 | 537 | 507 | 533 | 644 | 490 | 519 | 525 | 583 |
Expenses | 518 | 492 | 532 | 441 | 466 | 516 | 551 | 480 | 582 | 462 | 452 | 488 | 530 |
Operating Profit | 37 | 71 | 31 | 72 | 45 | 21 | -44 | 52 | 62 | 28 | 67 | 38 | 53 |
Other Income | 60 | 48 | 672 | 56 | 42 | 61 | 1,918 | 39 | 63 | 1,108 | 64 | 74 | 134 |
Profit before tax | 46 | 33 | 604 | 50 | 1 | -8 | 1,796 | 22 | 35 | 1,106 | 46 | 21 | 86 |
Tax % | 24% | 27% | 3% | 6% | 18% | 9% | -1% | 36% | 39% | 11% | 25% | 85% | 17% |
Net Profit | 35 | 24 | 584 | 47 | 1 | -8 | 1,811 | 14 | 21 | 988 | 35 | 3 | 71 |
EPS in Rs | 0.29 | 0.20 | 4.86 | 0.39 | 0.01 | -0.06 | 15.08 | 0.12 | 0.18 | 8.23 | 0.29 | 0.03 | 0.53 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 2,202 | 2,242 | 2,302 | 2,588 | 2,419 | 1,786 | 1,988 | 2,028 | 1,738 | 1,993 | 2,127 | 2,243 | 2,327 |
Expenses | 1,729 | 1,812 | 1,880 | 1,996 | 2,101 | 1,575 | 1,702 | 1,716 | 1,677 | 1,969 | 1,864 | 2,066 | 2,160 |
Operating Profit | 473 | 430 | 422 | 592 | 318 | 210 | 286 | 312 | 61 | 24 | 264 | 177 | 167 |
Other Income | 61 | 127 | 279 | 99 | 125 | 422 | 366 | 150 | 187 | 3,134 | 206 | 848 | 930 |
Interest | 1 | 1 | 2 | 4 | 1 | 3 | 1 | 0 | 0 | 70 | 199 | 237 | 245 |
Depreciation | 124 | 128 | 140 | 151 | 136 | 92 | 98 | 104 | 108 | 117 | 121 | 128 | 134 |
Profit before tax | 409 | 428 | 559 | 536 | 306 | 537 | 553 | 359 | 140 | 2,971 | 150 | 661 | 717 |
Net Profit | 324 | 361 | 369 | 519 | 238 | 493 | 441 | 280 | 86 | 2,848 | 119 | 609 | 668 |
EPS in Rs | 2.70 | 3.01 | 3.07 | 4.33 | 1.99 | 4.11 | 3.67 | 2.34 | 0.72 | 23.72 | 0.99 | 5.07 | 5.51 |
Dividend Payout % | 31% | 28% | 27% | 12% | 25% | 12% | -0% | -0% | 70% | 6% | 50% | 10% | – |
Standalone figures in ₹ crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 100 | 100 | 100 | 100 | 300 | 300 | 600 | 600 | 600 | 600 | 600 | 600 | 668 |
Reserves | 2,318 | 2,484 | 5,897 | 6,441 | 6,439 | 6,815 | 6,937 | 7,307 | 7,493 | 10,316 | 10,312 | 10,924 | 15,315 |
Borrowings | 121 | 82 | 370 | 134 | 133 | 71 | 4 | 2 | 77 | 1,301 | 2,043 | 2,876 | 2,543 |
Other Liabilities | 679 | 667 | 732 | 794 | 855 | 1,054 | 770 | 665 | 699 | 813 | 813 | 1,221 | 1,295 |
Total Liabilities | 3,218 | 3,333 | 7,098 | 7,469 | 7,727 | 8,240 | 8,311 | 8,574 | 8,869 | 13,030 | 13,768 | 15,621 | 19,821 |
Fixed Assets | 949 | 914 | 894 | 938 | 903 | 1,101 | 793 | 798 | 870 | 961 | 958 | 1,114 | 1,080 |
Gross Block | 1,730.00 | 1,832.10 | 1,934.40 | 2,128.90 | 2,236.70 | 2,581.30 | 1,993.30 | 2,098.10 | 2,277.10 | 2,479.70 | 2,586.80 | 2,838.60 | – |
Accumulated Depreciation | 780.70 | 917.80 | 1,040.60 | 1,190.90 | 1,334.10 | 1,480.20 | 1,200.10 | 1,300.00 | 1,406.90 | 1,518.30 | 1,628.40 | 1,725.10 | – |
CWIP | 102 | 58 | 172 | 241 | 318 | 254 | 152 | 179 | 285 | 344 | 560 | 701 | 822 |
Investments | 493 | 165 | 3,853 | 3,888 | 4,199 | 4,093 | 4,953 | 5,413 | 5,280 | 9,271 | 9,318 | 11,383 | 14,133 |
Other Assets | 1,674 | 2,196 | 2,179 | 2,402 | 2,307 | 2,792 | 2,413 | 2,184 | 2,434 | 2,454 | 2,932 | 2,424 | 3,787 |
Total Assets | 3,218 | 3,333 | 7,098 | 7,469 | 7,727 | 8,240 | 8,311 | 8,574 | 8,869 | 13,030 | 13,768 | 15,621 | 19,821 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operating Activity | 186 | 125 | 208 | 186 | 355 | 110 | 387 | 478 | 48 | 219 | -123 | 624 |
Cash from Investing Activity | 51 | 145 | -313 | 104 | -553 | 315 | -189 | -628 | -302 | -1,173 | -295 | -992 |
Cash from Financing Activity | -187 | -158 | 73 | -238 | -55 | -208 | -129 | 28 | 112 | 1,039 | 344 | 495 |
Net Cash Flow | 50 | 112 | -32 | 52 | -252 | 217 | 69 | -122 | -142 | 86 | -74 | 127 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 82 | 90 | 80 | 113 | 112 | 184 | 105 | 106 | 147 | 121 | 180 | 135 |
Inventory Days | 131 | 148 | 187 | 190 | 195 | 371 | 236 | 197 | 245 | 208 | 260 | 296 |
Days Payable | 99 | 109 | 146 | 159 | 202 | 298 | 230 | 170 | 172 | 169 | 175 | 288 |
Cash Conversion Cycle | 115 | 129 | 121 | 144 | 105 | 257 | 111 | 133 | 220 | 159 | 265 | 143 |
Working Capital Days | 52 | 76 | 42 | 108 | 87 | 214 | 154 | 122 | 181 | 151 | 244 | 30 |
ROCE % | 17% | 17% | 10% | 8% | 4% | 5% | 5% | 5% | 2% | 2% | 3% | 2% |
Direct from BSE filings, auto-summarised
External media mentions & references
Editorial & research coverage
Dec 2025
Dec 2025
Dec 2025
Nov 2025
Aug 2025
May 2025
May 2025
Feb 2025
Nov 2024
Aug 2024
Jun 2024
May 2024
Feb 2024
Nov 2023
Aug 2023
May 2023
Feb 2023
Nov 2022
Nov 2022
Aug 2022
Jul 2022
May 2022
Apr 2022
Apr 2022
Feb 2022
Jan 2022
Nov 2021
Oct 2021
Sep 2021
Sep 2021
Jul 2021
May 2021
Apr 2021
Jan 2021
Oct 2020
Sep 2020
Jul 2020
Jun 2020
Jun 2020
Feb 2020
Dec 2019
Dec 2019
Oct 2019
Sep 2019
Sep 2019
Jul 2019
Jun 2019
May 2019
Feb 2019
Nov 2018
Sep 2018
Jun 2018
Mar 2018
Feb 2018
Oct 2017
Sep 2017
Apr 2017
Mar 2017
Feb 2017
Oct 2016
Jul 2016
Apr 2016
Jan 2016
Oct 2015
Jul 2015
Stock Analysis
Biocon Limited is an innovation-led global biopharmaceutical company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune.
The consolidation of Biocon Biologics (BBL) into a wholly-owned subsidiary, supported by a substantial QIP fundraising, aims to create a unified global biopharmaceutical leader, unlock value, and leverage combined strengths to bolster Biocon's position in key therapeutic areas like diabetes, oncology, and immunology.
Currently no data available for Order Book.
Currently no data available for Key Red Flags.
Integration of Biocon Biologics (BBL) as a wholly-owned subsidiary expected by March 31, 2026.
Corporate Announcements
